SPONSOR
SCRI Development Innovations, LLC
Total Trials
3
Recruiting
3
Phases
Phase 2
SCRI Development Innovations, LLC is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Limited Stage Small Cell Lung Cancer, Multiple Myeloma, Breast Cancer.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — SCRI Development Innovations, LLC
How many clinical trials has SCRI Development Innovations, LLC sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by SCRI Development Innovations, LLC, of which 3 are actively recruiting participants. These trials cover conditions including Limited Stage Small Cell Lung Cancer, Multiple Myeloma, Breast Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does SCRI Development Innovations, LLC research focus on?
SCRI Development Innovations, LLC clinical trials span Limited Stage Small Cell Lung Cancer, Multiple Myeloma, Breast Cancer. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a SCRI Development Innovations, LLC clinical trial?
To participate in a SCRI Development Innovations, LLC trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all SCRI Development Innovations, LLC trials with current recruitment status updated daily.
Clinical Trials by SCRI Development Innovations, LLC
NCT06773910 Phase 2
Recruiting
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
NCT05972135 Phase 2
Recruiting
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Multiple Myeloma
NCT05748834 Phase 2
Recruiting
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
Breast Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology